Capricor Therapeutics (CAPR) be the next buy?
What’s up with Capricor Therapeutics?
Capricor Therapeutics (CAPR) opened at $5.77, which means the stock is down 8.01% from yesterday’s closing price of 5.99. Today, the company has a high of $5.90 and a low of $5.12. The company has a market cap of $68.68 million with a 52-week high of $11.08 and a 52-week low of $0.88.
What about the future for Capricor Therapeutics?
The high forecast for Capricor Therapeutics is $10.00 while the low is $8.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Capricor Therapeutics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information CAPR seems to be a safe buy.
About Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.